ABSTRAm. To study the effects of peroxisome proliferators on fetal biogenesis, 400 mglkg oral clofibrate was administered to pregnant mice beginning at d 6 of gestation.
Recent studies of human peroxisomal deficiency disorders have revealed that a dissociation may occur between the amounts of peroxisomal matrix proteins and those integral to the membrane (1, 2). Virtually no normal peroxisomes are visible in Zellweger syndrome fibroblasts because matrix proteins such as catalase are absent or relocated in the cytoplasm. Membraneassociated proteins such as DHAP-AT are completely deficient, perhaps because of degradation (3) . By contrast, proteins integral to the peroxisomal membrane (PMP) demonstrate amounts comparable to those of control cells.
Peroxisomal membranes are present in cells as "ghosts" with expanded and empty centers indicating sequential assembly and/ or independent regulation of matrix components (1) . Because peroxisomal biogenesis is assumed to occur by budding from preexisting peroxisomes (4) , membrane extension may occur first followed by organization of the internal milieu. Study of peroxisomal assembly with attention to matrix, membrane-associated, and integral membrane components will be required to understand biogenesis and its consequences for peroxisomal function and disease.
Ontogeny provides a natural system in which to examine the biogenesis of peroxisomes. The synthesis of membrane and matrix components may be integrated quite differently in separate tissues, judging by the 10-fold greater volumes of liver or kidney peroxisomes compared with the "microperoxisomes" of connective tissue or brain (3) . Although fetal peroxisomes would presumably derive from those in the egg, there have been few studies documenting their ontogeny. It is surprising that peroxisomes were not evident in rat liver before 14-1 5 d of gestation but are abundant by d 19 (5, 6) . Perhaps membrane components predominate before that time, with matrix components being synthesized later in development. Briere (7) identified peroxisomes in fetal kidney, and they are present in human chorionic villi at about 10 wk gestation (8) . The few studies available are consistent with a gradual increase of peroxisomes in most tissues as mammalian development progresses, with the highest activities of peroxisomal enzymes in liver and kidney (9, 10). This pattern continues during postnatal life in rats, with activities of peroxisoma1 /3-oxidation enzymes peaking at birth in liver and at about 70 d in heart (1 1). No studies have examined the coordinated ontogeny of peroxisomal membrane and matrix proteins as reported here.
Additional understanding of biogenesis might be provided if peroxisomal ontogeny could be manipulated by administering peroxisome proliferators such as clofibrate or phthalate ester plasticizers (10). These agents in fact produce a pleiotypic response with proliferation of peroxisomes and other organellar components such as the endoplasmic reticulum. Chronic administration to rats also results in a high incidence of hepatocarcinoma (1 0). Intriguing aspects of the proliferation reaction include species specificity (12) and the inductive ability of certain peroxisomal substrates (13). Clofibrate is active as a peroxisome proliferator in rodents, but has not been useful as a treatment for human peroxisomal deficiency disorders (14). In rats, selec-tive amplification of peroxisomal components is demonstrated, with certain enzymes involved in peroxisomal P-oxidation increasing 20-to 30-fold, whereas catalase increases only 2-fold. These increases in enzyme activity appear to occur at the transcriptional level, based on studies with cDNA probes for acyl CoA oxidase and bifunctional enzyme (1 5) . Despite an intensive search for binding proteins that might mediate the proliferative response, the mechanism of proliferation is still unknown (16).
Only one group has examined the ability of maternal clofibrate treatment to induce fetal peroxisome proliferation (1 7, 18 ). An increase in rat liver peroxisome number and fatty acid oxidation enzymes suggested that fetal proliferation occurred. Here we confirm this observation in mice and examine the effect of maternal clofibrate on the matrix, membrane-associated, and integral membrane proteins of fetal peroxisomes. Animal studies. Breeding was initiated by placing one male mouse with four females overnight with d 0 of gestation beginning the following morning. Mice were weighed daily to determine pregnancy and clofibrate treatment (400 mg/kg) initiated at d 6 of gestation as a freshly diluted solution in peanut oil administered daily using Metafane (Pitman-Moore, Inc., Washington Crossing, NJ) anesthesia and an orogastric cannula. Control mothers received equivalent volumes of peanut oil. Mice were killed by cervical dislocation at 13, 15, 17, and 19 d gestation. Maternal (brain, lung, liver, kidney) or fetal (brain, lung, liver, kidney, placenta) tissues were dissected rapidly and immediately frozen on a slab of dry ice. Before enzyme or immunoblotting assays, tissues were thawed and suspended in 0.25 M sucrose using a hand-held glass homogenizer. Three separate breeding experiments were performed, with tissues from all the fetuses in a given litter being combined in one homogenate. Tissues from mothers were homogenized individually. For enzymes, duplicate assays were performed on each tissue homogenate and the six values from three experiments averaged for mean and SEM. The significance of differences between clofibrate-exposed and control tissue mean values was assessed by the I test ( p < 0.05).
MATERIALS A N D METHODS

Materials
Enyzme assays. Peroxisomal marker enzymes included the matrix enzyme catalase, assayed by the method of Peters et a/. (19) , and the membrane associated enzyme DHAP-AT. DHAP-AT was assayed by the method of Jones and Hajra (20) after synthesizing "P-DHAP from "P-P04 and 3-phosphoglycerate kinase/glyceraldehyde-3-phosphate dehydrogenase (BoehringerMannheim, Indianapolis, IN). Conversion of 1 nmol -"P-DHAP into lipid soluble (acylated) form per rnin represented 1 unit of activity. A similar assay (21) was employed for GP-AT, which is mainly localized to microsomes. The mitochondrial marker was cytochrome c oxidase assayed by the method of Leighton el a/. (22) . Lactate dehydrogenase assayed by the method of Racker (23) was employed as a cytoplasmic marker, and acid phosphatase assayed with nitrophenyl phosphate (Sigma kit no. 435) was a marker for lysosomes. The sp act of these enzymes were based on pmol of substrate converted per min. Protein was quantitated by the method of Bradford (24) or, in the presence of SDS, by the method of Lowry (25) after trichloroacetic acid precipitation.
MoziseperoxisomepuriJication. Four 6-to 8-wk-old mice were killed by cervical dislocation and their livers (about 9 g total) diced in 27 mL cold 0.25 M sucrose, 10 mM Tris-HC1 pH 7.4, 1 mM EDTA. Tissue disruption was performed in a PotterElvesham homogenizer with a smooth pestle (50-mL vessel) mounted on a rotary motor (1 500 rpm, one pass taking 1 min). Differential centrifugation was performed at 4" essentially as described by Leighton et a/. (22) using a Beckman 52-2 1 centrifuge, a type JA-20 rotor, and 50-mL polyethylene tubes. A "light mitochondrial" or L fraction was obtained after 1) centrifuging three times for 10 min at 2250 rprn (600 x g) and discarding the pellet (nuclear debris); 2) centrifuging three times for 10 min at 5250 rprn (3300 x g) and discarding the pellet (mitochondria), and 3) centrifuging three times for 10 rnin at 14 500 rprn (25 000
x g) and retaining the pellet. At each stage, the initial pellet was homogenized in an equivalent volume of fresh sucrose buffer and centrifuged again under the indicated conditions. Four 0.7-mL aliquots of the L fraction were layered over 2.5 mL of 27.6% Nycodenz in 3.4 mL polycarbonate tubes and centrifuged for 1 h at 75 000 rprn (23 1 840 x g) in the TLA 100.3 rotor at 4". The loose pellet (N fraction) was collected with residual Nycodenz after aspiration of the supernatant and placed on a Nycodenz gradient consisting of six 2-mL shelves (44, 40, 36, 32, 28, and 24%) pipetted and equilibrated overnight at 4" in 12-mL polycarbonate tubes. N fraction ( 1 mL) was overlaid (sinking about 1 mL into the gradient) and centrifugation was 6 h at 35 000 rprn and 4" in a SW 4 1 swinging bucket rotor. The peroxisomal band, about 4 /~ down the gradient, was aspirated with a needle (NG fraction), diluted ' / 3 with 0.25 M sucrose, and concentrated by centrifuging for 10 min at 12 000 rprn and 4" in the Beckman JA-20 rotor. Membranes were purified as described (26) by diluting 0.06 mL (0.2-0.5 mg protein) with 2.94 mL of 100 mM sodium carbonate pH 1 1.5, centrifuging 1 h at 75 000 rprn and 4" in the Beckman TLA 100.3 rotor, and suspended in 300 pL of normal saline.
Preparation of antibodies to mouse PMP. The peroxisomal membrane suspension was combined with 1.5 mL of complete Freund's adjuvant (Sigma) and divided into 20 intradermal injections along the back of each of two 20-wk-old New Zealand White rabbits. In 2 wk, a second s.c. injection was given, which contained an equivalent amount of PMP. Serum collected 10 wk later and at 2-wk intervals thereafter was frozen at -70°C until used.
SDS-PAGE and immunoblot analysis. Gradient fractions or organ homogenates were diluted I/?-% in loading buffer and applied to 7.5% SDS-PAGE gels in a Bio-Rad Miniprotean I1 apparatus using protocols supplied by the manufacturer. Electrophoresis was for 0.5 h at 200 V (50 mA) and protein blotting was accomplished using a BioRad Mini Trans-Blot apparatus and nitrocellulose membranes. Blocking with 5% BSA, 10 mM Tris-HCI pH 7.4, 150 mM NaCl for 18-24 h at 25°C was followed by incubation with rabbit antiserum diluted 1:100 in 50 mM Tris-HCI pH 7.4, 0.15 M NaC1, 5 mM EDTA, 0.25% gelatin, 0.05% NP-40 (Sigma) for 1 h at 25°C. Development was with goat anti-rabbit serum and the peroxidase detection kit provided by Cappel. The intensity of PMP 70 bands was qualitatively converted to &mg of homogenate by comparison to the standard curve.
Electron microscopy. For assessment of purity, peroxisome suspensions were stored at -70"C, then diluted into 0.25% glutaraldehyde (Sigma) and stored at room temperature until examination. After centrifugation for I rnin in a microcentrifuge, the pellet was postfixed with osmium tetroxide and embedded in Epon 8 12. Adult and fetal mouse liver specimens were stained with the catalase substrate diaminobenzidine ( l8), then processed for electron microscopy as above.
RESULTS
The purification of peroxisomes from mouse liver was accomplished by modifications of prior methods for differential and Nycodenz gradient centrifugation (22,27,28). The final gradient 258 WILSON (Na) fraction was 25-fold enriched in catalase sp act with less than I % contamination by other organelles as shown in Figure  1 B. Injection of sodium carbonate-treated (26) NG fraction into rabbits generated antisera that detected 145-, 70-, 60-, 55-, 36-, and 22-kD peptides after SDS-PAGE and immunoblotting. The specificity of these antibodies for PMP is suggested by the codetection of 145-, 70-, 60-, and 55-kD peptides with the peroxisoma1 marker enzyme DHAP-AT in high-density fractions of the Nycodenz gradient (Fig. IA) . No peptides are visualized when the PMP antiserum is used for immunoblotting of purification fractions depleted in peroxisomes (data not shown). PMP 70 was the most prominent peptide detected by all antisera as illustrated by the developmental studies described below.
The proliferative effect of clofibrate on peroxisomes in both maternal and fetal tissues is demonstrated by electron microscopy and assay of peroxisomal proteins. Peroxisome density in maternal liver after 7 d of oral clofibrate administration (Fig.  2 5 ) was increased almost 2-fold compared with control maternal liver ( Fig. 2A) . Additional experiments showed that peroxisome proliferation in maternal liver plateaued after 6 d of oral clofibrate administration, meaning that maximal maternal proliferation had been attained throughout the period of fetal sampling. There was also a striking proliferation of the endoplasmic reticulum and an increased number of peroxisomes (arrows) in 15-d fetal liver from clofibrate-treated (Fig. 2 0 ) versus control (Fig.  2C) pregnancies. Peroxisomal density could not be reliably quantitated in fetal tissues because of relatively poor diaminobenzidine staining (Fig. 2 C and D) .
The rabbit antiperoxisomal membrane antibody with bias toward PMP 70 allowed a comparison of this peptide in clofibrate-treated and control tissues. The amount of PMP 70 detected in immunoblotting experiments could be qualitatively estimated using the standard curve shown in the upper panel of Figure 3 . Duplicate aliquots of sodium carbonate-purified membranes from the mouse NG fraction were converted to known amounts of PMP 70 by assuming equimolar composition of PMP 145,70,36, and 22 in the membrane as suggested by SDS-PAGE gels stained with Coomasie blue or silver (29). This assumption implies that 25% of total membrane protein mass is PMP 70, allowing conversion of band intensity to pg of PMP 70 per mg of tissue homogenate loaded on the gel. Although this conversion factor may not be accurate, comparisons of PMP 70 among fetal tissues should be valid within a factor of 2.
The middle panel of Figure 3 demonstrates clofibrate-induced increases in PMP 70, which are most striking in maternal liver (lane 2 versus 1) and kidney (lane 6 versus 5). Proportionally less PMP 70 is seen in maternal tissues such as brain (lanes 3 and 4) and lung (lanes 7 and 8), which contain microperoxisomes. A response to clofibrate is not evident in these tissues. The lower panel of Figure 3 demonstrates an increase in fetal liver PMP 70 both during ontogeny (lanes 5-8 representing gestational d 19-13) and as an effect of maternal clofibrate administration (lanes 1-4) .
The average levels of PMP 70 in maternal tissue homogenates as measured in three separate experiments are shown in Figure  4 alongside sp act for the peroxisomal enzymes DHAP-AT and catalase, the microsomal enzyme GP-AT, the lysosomal enzyme acid phosphatase, and total protein. > membrane-associated protein (DHAP-AT) > matrix protein (catalase). Maternal kidney also shows some response to clofibrate and there is increased activity of DHAP-AT in the brains of treated mothers (Fig. 4) . Clofibrate-treated livers are larger and yield more total protein in mothers, and this effect was noted for the liver and kidney of certain fetuses. Minimal differences in acid phosphatase or GP-AT activity were noted for maternal tissues or fetal liver (Fig. 4) . Figure 5 shows two sets of immunoblots contrasting the levels of PMP 70 in other fetal tissues from control or clofibrate-treated pregnancies. Those in Figure 5A (Fig. 5B ). An increase of PMP 70 with normal ontogeny is also documented in fetal liver (Fig.  3, bottom panel, lanes 8-5; Fig. 55, lanes 1-4) . Nonspecific reaction of antibody to molecular weight markers (righi lane) is seen in some blots depicted in Figure 5 A and B. This reaction probably reflects absorption to concentrated protein standards and has never been observed in experimental lanes.
The results from three separate breeding experiments are summarized in Figure 6 , showing fetal tissue levels of peroxisomal or marker proteins as a function of maternal clofibrate administration. Enhancement of fetal PMP 70 by clofibrate occurs to some degree in all fetal tissues, but is most striking in fetal liver (H) and kidney (K). Enhancement of DHAP-AT sp act is also evident in all fetal tissues, and the effects of maternal clofibrate administration on these fetal peroxisomal membrane proteins can be seen by 13 d gestation in lung and placenta. Some variability of response in the three separate experiments summarized in Figure 6 is indicated by the standard error bars, but these were not calculated for PMP 70 because of the qualitative nature of the results. As with maternal and fetal liver (Fig. 4) , the enhancement of membrane-associated proteins appears greater than that of the matrix protein catalase in most fetal tissues (Fig. 6) . In fact, fetal lung and kidney catalase levels were actually higher in control pregnancies at certain stages of gestation. The amounts of peroxisomal proteins increase during normal ontogeny in all fetal tissues except perhaps in placenta. Maternal clofibrate increases total tissue protein only in fetal liver and kidney, the organs with the largest and most abundant peroxisomes (Fig. 6) . No consistent differences in the sp act of acid phosphatase or GP-AT are seen in most fetal tissues, with the exception of a developmental decrease in acid phosphatase sp act in fetal kidney. There was a striking increase in the microsomal enzyme GP-AT in placentas from clofibrate-treated pregnancies (Fig. 6 ). As observed in human placenta (29), levels of mouse placenta peroxisomal proteins remain fairly constant in midgestation with a decrease in later pregnancy.
DISCUSSION
Several laboratories have demonstrated the presence of 150-, 70169-, and 22-kD PMP in rat (28, 30) or human (I 1) tissues. Additional species of 53-, 42-, 36-, 28-, and 26-kD have also been seen in rat liver extracts, with the 42-, 28-, and 26-kD species postulated to be degradation products of the 70-kD protein (30) . No studies of mouse PMP have been reported, despite the potential in this organism to manipulate peroxisome structure through use of transgenic technology. We have detected PMP of 145-, 70-, 60-, 55-, 36-, and 22-kD PMP by protein staining or immunoblotting after SDS-PAGE of mouse liver homogenates (29). The immunoblot in Fig. 1 A demonstrates the 145-, 70-, 60-, and 55-kD peptides with the 36-and 22-kD peptides having run off the gel. The 145-, 70-, 36-, and 22-kD peptides appear highly conserved when liver homogenates of mouse, rat, and man are compared, and the variable detection of 60-and 55-kD peptides suggest that they are breakdown products of the 145-and 70-kD peptides (29). Rabbit antisera prepared against purified peroxisomal membranes from mouse liver uniformly exhibit biased detection of the 70-kD peptide, as illustrated in Figures IA, 3 , and 5. Increased abundance, accessibility, or immunogenicity of this peptide relative to other PMP may be responsible. Although a conversion factor relating immunoblot band intensity to PMP 70 abundance cannot be reliably calculated, an estimate was made assuming equimolar ratios of PMP 145,70,36, and 22 in the peroxisomal membrane.
Comparison to the standard curve in Figure 3 then allowed semiquantitative comparisons of PMP 70 levels among maternallfetal tissue homogenates provided care was taken to ensure PMP 70 levels were not saturating for the immunoblot assay.
In agreement with a prior study in the rat (17, 18) , the administration of clofibrate to pregnant mice is shown here to cause amplification of peroxisomal proteins in several fetal tissues. Whereas the rat experiments focused mainly on peroxisoma1 matrix proteins such as catalase or those responsible for fatty acid @-oxidation (1 7, 18) , the data presented here demonstrate an effect on two other classes of peroxisomal proteins-integral membrane proteins (PMP 70) and the membrane-associated enzyme DHAP-AT-that is a key step in plasmalogen synthesis (9). Just as uncoupling of peroxisomal membrane and matrix synthesis is evident in certain disease states, the experiments summarized in Figures 4 and 6 show an increased clofibrate response of these membrane proteins relative to catalase. This response is consistent with initial synthesis of peroxisomal membranes and membrane proteins during biogenesis followed by import of matrix components. Both PMP 70 and DHAP-AT were detected in most fetal tissues by 13 d of gestation, as was the matrix enzyme catalase. Because catalase can also be located in the cytoplasm, the detection of activity does not prove that a peroxisomal matrix has been assembled at this time in gestation. Failure to identify peroxisomes histologically early in gestation (6, 7) may reflect the primacy of peroxisomal membrane synthesis in both ontogeny and postnatal biogenesis. Consistent with this sequence is the decreased staining of fetal ( Fig. 2 C and D) versus maternal ( Fig. 2A and B) liver peroxisomes with the diaminobenzidine reaction.
The ability to manipulate fetal peroxisomal membrane synthesis through administration of clofibrate to the mother is clearly demonstrated by the data summarized in Figures 4 and 6 . Fetal liver, lung, kidney, and placenta show evident increases in peroxisomal enzyme activities after initiating maternal clofibrate treatment at gestational d 6. The response is most clear at 17-1 9 d gestation but may occur earlier inasmuch as early gestational expression in liver, as with later expression in brain or lung, is near the limits of detection for the immunoblot assay. The presence of peroxisomal components in mouse placenta early in gestation correlates with the demonstration of peroxisomes in human chorionic villi (8) . More definitive evaluation of peroxisome biogenesis in the early mammalian embryo should soon be possible because a complementary DNA clone for the PMP FETAL PER 70 mRNA from rat liver has been isolated (32). Preliminary analysis of this clone demonstrates that it is a member of an ATP-binding protein family and supports the view that PMP are important structural components of the peroxisome.
Peroxisomal biogenesis during ontogeny, particularly because it can be regulated by proliferators such as clofibrate, offers a useful system for study of peroxisomal assembly. Peroxisomes were first thought to derive from the endoplasmic reticulum because electron micrographs may show connections between these organelles. The demonstration of unique polypeptides in peroxisomal membranes replaced this model with one asserting that new peroxisomes are formed by budding from previously existing peroxisomes (33). Peroxisomal fission is more a branching process than division, inasmuch as serial microscopy demonstrates a labyrinthine network of peroxisomal structure that appears circular only on cross-section (34). Integration of membrane proteins may occur by a different route than import of soluble proteins that are synthesized on free polysomes and targeted by carboxy-terminal or internal tripeptide signals (4, 34). The experimental system defined here provides the means to answer such questions through the combined effects of ontogeny and proliferative agents on a genetically manipulable organism.
